Indivior ends PAM drug collab with Addex ahead of Supernus merger
Indivior Pharmaceuticals ended its collaboration with Addex Therapeutics on positive allosteric modulators (PAMs) ahead of its merger with Supernus. Indivior returned all PAM assets to Addex, which plans to explore strategic options for advancing its GABAB receptor portfolio. Indivior had previously discontinued another collaboration in April. The merger with Supernus is expected to create a new CNS-focused biopharma.
How this was made
The 30-second read
Why it matters
The collaboration termination may affect INDV's near‑term valuation but could streamline the combined entity; Addex gains strategic flexibility.
Market read
Both tickers are directly impacted by the partnership termination and upcoming merger, offering short‑term trading considerations.
What to watch
Potential cash consideration or milestone payments tied to the asset return were not disclosed.
Background
Indivior is preparing for an all‑stock merger with Supernus, while Addex is a Nasdaq‑listed biotech focused on GABAB modulators.
Ticker impact
Indivior ends its PAM collaboration with Addex as it prepares for its merger with Supernus.
Expect modest price pressure on INDV pending merger completion.
Collaboration termination signals a shift in R&D focus and may raise concerns about pipeline progress.
Market effects
Both companies operate in the CNS biotech space; the news may shift sentiment across GABAB‑targeted therapeutics.
US biotech sector may see slight volatility as merger‑related restructuring unfolds.
Limited to investors tracking CNS drug pipelines and merger arbitrage.
Counterpoint
The termination could be a strategic cleanup ahead of the merger, reducing overlap and improving long‑term value.
Key entities
- CompanyIndivior Pharmaceuticals
NASDAQ‑listed CNS biotech preparing to merge with Supernus.
- CompanyAddex Therapeutics
NASDAQ‑listed biotech developing GABAB PAMs.
